IO102-IO103

IO102-IO103 (IO102, IO103) is a peptide (immunotherapeutic vaccine) developed by IO Biotech. Its target is PD-L1 (the sponsor names IDO1 and PD-L1). The sponsor states: IO102-IO103 comprises an IDO peptide antigen (IO102) and a PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) and given subcutaneously to stimulate an immune response against IDO- and PD-L1-expressing cells, dosed alongside pembrolizumab in advanced melanoma. ClinicalTrials.gov describes the intervention as: IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05155254 (IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)), in melanoma and head and neck squamous cell carcinoma. The largest, NCT05155254, plans to enrol 407 participants (actual) with primary completion expected 2025-05-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.